Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
Anavex Life Sciences Corp. (NASDAQ:AVXL) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. The US$619m market-cap company's loss lessened since it announced a US$48m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$42m, as it approaches breakeven. The most pressing concern for investors is Anavex Life Sciences' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Anavex Life Sciences Corp.(納斯達克:AVXL)可能即將在其業務中取得重大成就,因此我們想爲該公司投下一些光。Anavex Life Sciences Corp.是一家處於臨床階段的生物製藥公司,致力於開發治療中樞神經系統疾病的治療藥物。這家市值爲61900萬美元的公司自那一整個財政年度宣佈出現4800萬美元的虧損以來,虧損有所減少,相比最近單季度虧損4.2千萬美元,接近盈虧平衡。對於投資者而言,Anavex Life Sciences的盈利路徑是最爲緊迫的問題 - 它何時能夠實現盈虧平衡?我們已經爲分析師對該公司的預期、其盈利年份以及其隱含增長率做了簡要概述。
According to the 3 industry analysts covering Anavex Life Sciences, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$80m in 2025. So, the company is predicted to breakeven just over a year from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 48%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
根據覆蓋Anavex Life Sciences的3位行業分析師的情況,共識是盈虧平衡即將到來。他們預計該公司將在2024年承受最終虧損,然後在2025年實現8000萬美元的正收益。因此,預測該公司將在一年多之後實現盈虧平衡。該公司需要以何種年增長率才能在該日期實現盈虧平衡?使用最佳擬合線,我們計算出48%的平均年增長率,這相當樂觀!如果該業務增長速度較慢,它將在預期之後的時間點變得盈利。
We're not going to go through company-specific developments for Anavex Life Sciences given that this is a high-level summary, however, take into account that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
鑑於這是一份高層摘要,我們將不會詳細介紹Anavex Life Sciences的公司特定發展情況,但是考慮到生物技術公司,根據產品開發階段的不同,現金流可能出現不規律的情況。這意味着,隨着公司開始收穫早期投資的好處,大幅增長率並不罕見。
One thing we'd like to point out is that Anavex Life Sciences has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
我們想指出的一件事是,Anavex Life Sciences的資產負債表上沒有債務,對於一個燃燒現金的生物技術公司,這是相當不尋常的,一般而言,相對於股本,這類公司的債務較高。該公司目前完全依靠股東的資金運營,沒有債務義務,降低了還款的擔憂,使其成爲一個風險較低的投資。
Next Steps:
下一步:
This article is not intended to be a comprehensive analysis on Anavex Life Sciences, so if you are interested in understanding the company at a deeper level, take a look at Anavex Life Sciences' company page on Simply Wall St. We've also put together a list of important aspects you should look at:
這篇文章並不意在對anavex life sciences進行全面分析,因此如果您有興趣更深入地了解該公司,請查看Simply Wall St上anavex life sciences公司頁面。我們還整理了一份您應該關注的重要方面列表:
- Valuation: What is Anavex Life Sciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Anavex Life Sciences is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Anavex Life Sciences's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Anavex Life Sciences今天的價值是多少?未來的增長潛力已經被市場計入價格了嗎?我們免費的研究報告中的內在價值信息圖幫助您可視化了解Anavex Life Sciences目前是否被市場錯誤定價。
- 管理團隊:經驗豐富的管理團隊使我們對企業的信心增加-請查看Anavex Life Sciences董事會和首席執行官的背景。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。